Similar articles

• Overview of current therapeutic options in type 2 diabetes. Rationale for combining oral agents with insulin therapy.

  Buse JB. Buse JB. Diabetes Care. 1999 Apr;22 Suppl 3:C65-70. Diabetes Care. 1999. PMID: 10189565 Review. No abstract available.
• [Insulin sparing and metabolic control with metformin-insulin combination].

  Isnard F. Isnard F. Journ Annu Diabetol Hotel Dieu. 1997:305-25. Journ Annu Diabetol Hotel Dieu. 1997. PMID: 9296986 Review. French. No abstract available.
• An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin: response to Barnett et al.

  Kanna B, Abreu-Pacheco H. Kanna B, et al. Diabetes Care. 2007 Feb;30(2):445-6; author reply 446. doi: 10.2337/dc06-2031. Diabetes Care. 2007. PMID: 17259531 No abstract available.
• Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus.

  Strowig SM, Raskin P. Strowig SM, et al. Diabetes Obes Metab. 2005 Nov;7(6):633-41. doi: 10.1111/j.1463-1326.2004.00440.x. Diabetes Obes Metab. 2005. PMID: 16219007 Review.
• [Impact of intensive blood glucose control with hypoglycemic sulfamides, metformin or insulin on complications of non-insulin dependent diabetes].

  André P. André P. Rev Epidemiol Sante Publique. 1999 Mar;47(1):93-5. Rev Epidemiol Sante Publique. 1999. PMID: 10214683 French. No abstract available.